The first member of a new class of osteoporosis drugs reduced spinal fractures by about two-thirds in post-menopausal women and in men undergoing hormone-deprivation therapy for prostate cancer, according to two studies released online yesterday by the New England Journal of Medicine.

The drug, called denosumab, is the first to block production of cells called osteoclasts that break down bones, and physicians have high hopes for it because of its efficacy, ease of administration and apparent lack of severe side effects.

But it is also a biological agent, rather than a chemical, meaning it is difficult to produce, and it figures to be the highest-priced osteoporosis drug in a crowded marketplace.

The most well-known of these drugs, Fosamax, is in a class known as bisphosphonates. These drugs actually kill osteoclasts but carry the risk of stomach and esophageal irritation and have been linked to jaw necrosis. Already, many insurance companies are pushing physicians to prescribe alendronate -- the generic version of Fosamax -- because it costs only about $100 per year.

Advertise with us

Amgen, the manufacturer of denosumab, has not yet said how much the drug is going to cost, but analysts expect it to be at least $2,000 per year and predict yearly sales of $2 billion to $3 billion.

But some medical experts said a high price would discourage use. "If it is going to be quite a bit higher than the next-most-expensive drug, I don't see that it is going to be used so widely," said Dr. Frederick Singer, director of the endocrine/bone disease program at John Wayne Cancer Institute in Santa Monica, Calif., who was not involved in the research.

An advisory committee of the Food and Drug Administration will meet tomorrow to consider Amgen's application for approval of the drug, to be called Prolia, for treating osteoporosis in women and in men being treated for prostate cancer. If approved, it would be the first drug specifically approved for treating such men, although bisphosphonates have been approved for treating simple osteoporosis.

The market for osteoporosis drugs is estimated at more than $5 billion per year because of the large potential patient population. As many as half of women and 30 percent of men will suffer an osteoporosis-related fracture, according to the International Osteoporosis Foundation.

About one-third of the 2 million American men with prostate cancer undergo hormone-deprivation therapy in an effort to prevent release of the hormones that fuel the growth of tumors, sharply increasing their risk of osteoporosis.

Advertise with us

The two new trials were designed and funded by Amgen, and most of the researchers were Amgen employees or recipients of funds from the company. Nonetheless, osteoporosis experts were impressed with the results.

"From a scientific standpoint, these are outstanding publications," Dr. Singer said.

Previous studies have shown that other osteoporosis drugs can increase bone density in such men, but this is the first one to show that a drug can reduce fractures, the authors said.

Many of the patients in both studies reported soreness at the injection site and transient bone pain similar to arthritis. The drug caused eczema, an inflammation of the epidermis, in a few patients, and about 12 women got a serious skin infection called cellulitis.